Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-101 open-label extension in adults with alpha-1 antitrypsin deficiency emphysema
2023-508137-14-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of efdoralprin alfa in alpha-1 antitrypsin deficiency (AATD) and emphysema, sponsored by Sanofi. Primary endpoint: Treatment-emergent adverse events. Planned start Mar 2025; status: authorised.
02
Drugs
efdoralprin alfa
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2023-508137-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508137-14-00.